GLP-1 TV · 24 videos · newest first
Foundayo: experiences videos
Videos on life with Foundayo: what to know going in and what a day of eating looks like. 24 videos, all playable here. See what Foundayo costs by dose.
2:09:16Questions? Honest Answers! About GLP-1s, Zepbound , Wegovy, Foundayo? DOWNSIZED LIVE!DOWNSIZEDDetails8 key moments
This is a weekly live Q&A from the hosts of Downsized, a couple who say they are patients and not doctors. They say they have lost over 100 pounds (The speaker) and 50 pounds (The speaker) and kept it off.
- 15:20 Alcohol
- 23:14 Weigh-in and results
- 36:45 Cost and insurance
- 48:34 Side effects
- 1:07:05 Exercise and strength
- 1:21:20 Dose change
- 1:37:02 Stopping and maintenance
- 1:53:46 Weigh-in and results
- Weight loss mentioned: 18 lb
- Side effects mentioned: nausea, vomiting, constipation, diarrhea, fatigue, headache, hair loss and dehydration
19:35Foundayo Failed Me? How I Got Back on Track with MounjaroA Walk In My ShoesDetails
A video shares their experience with Mounjaro.
Everything about this video
2:11:43Got Questions About GLP-1s, Zepbound , Wegovy, Foundayo? DOWNSIZED LIVE!DOWNSIZEDDetails8 key moments
In this weekly live Q&A, the hosts of the channel say they are not doctors. The speaker says he went from 286.4 pounds to about 185 pounds, taking Zepbound, Mounjaro and compounded tirzepatide, with about a year at a 15 or 16 milligram dose.
- 2:19 Dose change
- 23:35 Food, protein and eating
- 32:58 Exercise and strength
- 58:24 Food, protein and eating
- 1:12:21 Dose change
- 1:36:14 Cost and insurance
- 1:45:15 Dose change
- 1:55:19 Weigh-in and results
- Weight loss mentioned: 100 lb
- Side effects mentioned: nausea, constipation, diarrhea and loose skin or face changes
2:07:42Got Questions About GLP-1s, Zepbound , Wegovy, Orforglipron? DOWNSIZED LIVE!DOWNSIZEDDetails8 key moments
This is a weekly live Q&A from the channel, hosted by married couple the speaker. They say they are patients, not doctors.
- 2:39 Cost and insurance
- 27:01 Dose change
- 32:06 Injection technique
- 50:26 Exercise and strength
- 1:08:16 Food, protein and eating
- 1:20:34 Dose change
- 1:36:11 Cost and insurance
- 1:52:40 Weigh-in and results
- Weight loss mentioned: 50 lb
- Side effects mentioned: nausea, constipation, fatigue, hair loss, heartburn or reflux, loose skin or face changes and muscle loss
20:42Foundayo: New "Ozempic in a Pill". Here's the Catch.Dr. Amin Hedayat, MDDetails8 key moments
The speaker, who describes himself as a physician, triple board-certified pathologist and assistant clinical professor of medicine, covers Foundayo (orforglipron), a daily pill from Eli Lilly that he says the FDA approved on April 1, 2026.
- 0:00 Is the New Ozempic Pill Dangerous?
- 3:08 How GLP-1 Weight Loss Drugs Actually Work
- 4:50 Why Old GLP-1s Required Injections
- 6:02 How the New Daily Weight Loss Pill Works
- 7:42 The Muscle Loss Trap: Why Your Scale is Lying
- 11:08 Ozempic Face & Muscle Wasting Explained
- 12:06 Strategy 1: The Protein Threshold (mTOR)
- 14:14 Strategy 2: Resistance Training & Mechanical Tension
- Weight loss mentioned: 40 lb
- Side effects mentioned: low appetite
7:51New Weight Loss Pill That Replaces Ozempic? - Foundayo ReviewDr KiddDetails3 key moments
The speaker reviews Foundayo (the captions spell it Foundeo), the brand name for orforglipron. He says the FDA approved it in April 2026 for managing obesity and that it is taken as one tablet a day.
- Side effects mentioned: nausea, constipation and diarrhea
21:22Foundayo For Obesity Care: The New Oral GLP-1Metabolic Health with Dr. Lindsay Ogle, MDDetails5 key moments
In this video, the speaker, an obesity medicine specialist, reviews orforglipron, sold as Foundayo, which she describes as the newest FDA approved obesity medication. She explains that it is an oral, non-peptide GLP-1 medication.
- 0:00 Introduction
- 3:39 Side effects
- 6:00 Dose change
- 16:33 Food noise and cravings
- 18:46 Cost and insurance
- Side effects mentioned: nausea and constipation
7:54A New Oral Small Molecule (Orforglipron) Released - It Might Beat the Peptides in a Key WayPhysionicDetails4 key moments
According to the video, orforglipron (earlier called LY3502970) is a new oral small molecule, not a peptide, that binds the same GLP-1 receptor as injectable peptides. The speaker says he pulled nine studies to understand how it works.
- 0:00 Introduction
- 1:14 GLP-1 - Good to see you Again!
- 4:00 Run that Name by me Again?
- 6:19 Scary Name, Scary Side Effects?
11:24Foundayo (Orforglipron): Is This GLP-1 Pill Really Better Than Ozempic Shots?Erik Richardson D.O.Details8 key moments
According to the video, Foundayo (orforglipron) is a once-daily oral GLP-1 for weight loss that the FDA has approved.
- 0:00 The Real Question
- 0:26 FDA Update (Post Initial Filming)
- 1:22 How It Compares to Other GLP-1
- 2:11 The Real Weight Loss Numbers
- 3:55 Who Should Switch
- 4:57 Who Should NOT Switch
- 6:30 Side Effects and Safety
- 8:44 How Do I Take It?
- Side effects mentioned: dehydration and pancreatitis
10:42GLP-1 Finally Comes in a Pill — Should You Switch to Foundayo?Dr. Dan | Obesity ExpertDetails8 key moments
The speaker, who presents as an obesity expert, explains what Foundeo (orforglipron) is and whether people on injectable GLP-1 medications should switch to it. He says it is an oral, non-peptide small molecule that binds GLP-1 receptors.
- 0:00 Foundayo - new GLP-1 pill
- 0:31 What is Foundayo?
- 0:56 Oral Semaglutide / Oral Wegovy
- 1:50 Foundayo’s big advantages
- 2:35 How does it compare to other GLP-1s?
- 3:54 A pill can’t skip the “Liver Check”
- 5:31 Small molecule concerns
- 6:12 Drug interactions
12:14Foundayo for Weight Loss: Why Doctors Are Now Recommending ItMedicine Made SimpleDetails4 key moments
According to the video, Foundayo (also called Orforglipron) is a newly approved once-daily oral pill for adults with obesity, or some adults with overweight who also have weight-related medical problems.
- Side effects mentioned: nausea, vomiting, diarrhea, headache, heartburn or reflux and dehydration
5:49Foundayo — The Weight Loss Pill That Shouldn't ExistT-PharmacyDetails6 key moments
According to the video, Eli Lilly's orforglipron, sold as Foundayo, was approved by the FDA on April 1st as a weight loss pill. The narrator says other large drug companies tried to make a pill like it and ended their own programs after liver injury signals in clinical trials.
- 0:00 Intro
- 0:53 Why Foundayo is nothing Ozempic
- 1:55 The real weight loss numbers
- 3:13 What happened to Pfizer's programs
- 4:07 What the label says about birth control
- 4:57 Where Foundayo actually fits
18:16New Weight Loss Pill Foundayo Better Than Zepbound?JulsWellnessWarriorDetails8 key moments
The speaker, a creator who says she has lost over 50 lb and is maintaining on Zepbound 12.5 mg weekly, compares the new Eli Lilly pill Foundayo (orforglipron) with injections and with the Wegovy pill.
- 0:00 Introduction to GLP-1 options
- 3:22 Clinical data and efficiency
- 8:43 Side effects and precautions
- 10:25 Medication cost and access
- 11:01 Injection delivery systems
- 12:15 Pill cost comparison
- 12:18 Daily vs weekly commitment
- 12:23 Convenience and needle phobia
- Side effects mentioned: constipation
10:40Lost and Foundayo: Should You Switch to the GLP-1 Pill?Barrick HealthDetails
A video looks at what life on Foundayo is like.
Everything about this video
12:17The Secret Daily Protocol To Master The Foundayo Weight Loss PillLawrence ReportingDetails6 key moments
According to the video, the narrator from the channel says the FDA approved the weight loss pill Foundayo on April 1st and that it reached the consumer market on April 6th.
- 0:00 The Biological Trap
- 1:11 The Paralyzed Stomach
- 3:44 The Dietary Minefield
- 6:29 The Liquid Threat
- 9:14 Tactical Hydration
- 10:26 The Financial Trap
- Side effects mentioned: nausea, heartburn or reflux, bloating and muscle loss
42:35The GLP-1 Revolution: Foundayo, Wegovy, and Zepbound ; What Every Patient Needs to KnowSugarMDDetails8 key moments
The speaker, an endocrinologist who presents on the channel, compares three obesity medications: Foundayo (an oral pill), Wegovy and Zepbound. He first explains the basics.
- 0:00 Introduction to new therapy
- 1:12 The obesity crisis context
- 2:58 Mechanism of action
- 5:57 Fondeo and oral therapy
- 8:50 Comparing treatment efficacy
- 11:39 Detailed breakdown by drug
- 16:00 The role of Fondeo
- 18:25 Clinical patient selection
- Side effects mentioned: muscle loss, low appetite and pancreatitis
9:00Foundayo™ Consumer Brief SummaryFoundayo™(orforglipron)Details
The manufacturer looks at what life on Foundayo is like.
Everything about this video
26:42Diabetes Dialogue: Orforglipron, Retatrutide, and Other GLP-1 UpdatesHCPLiveDetails8 key moments
In this episode of Diabetes Dialogue, hosts the speaker and Natalie Bellini review recent GLP-1 news. They start with the ACHIEVE 3 trial, a phase three head-to-head study of orforglipron against oral semaglutide in 1698 people taking metformin.
- 0:00 <Untitled Chapter 1>
- 0:01 Intro
- 0:22 Orforglipron in the ACHIEVE-3 trial
- 3:30 Side effects from orforglipron
- 10:28 Retatrutide in the TRIUMPH-4 trial
- 18:26 Topline data on Novo Nordisk's UBT251
- 21:47 Price cuts on Ozempic, Rybelsus, and Wegovy in 2027
- 26:26 Outro
- Side effects mentioned: nausea, constipation and diarrhea
14:35Why orforglipron could change weight loss managementProfessor G - PharmacologyDetails
A video looks at what life on Foundayo is like.
Everything about this video
9:25Orforglipron for Obesity Treatment (ATTAIN-1) | NEJM | Med Journal ClubMed Journal ClubDetails8 key moments
According to the video, the ATTAIN-1 trial tested once-daily orforglipron, an oral small-molecule GLP-1 agonist, in adults with obesity who do not have diabetes. The presenter describes it as a phase three, randomized, double-blind, placebo-controlled study run over 72 weeks.
- 0:00 Opening
- 0:10 Introduction
- 0:40 Background
- 1:34 Study Design
- 2:50 Outcomes
- 3:06 Results
- 4:51 Discussion
- 6:46 Clinical Relevance
10:44Orforglipron in Early Diabetes (ACHIEVE-1) | NEJM | Med Journal ClubMed Journal ClubDetails8 key moments
This video from the channel is a critical appraisal of the ACHIEVE-1 trial of orforglipron, published in the New England Journal of Medicine.
- 0:00 Opening
- 0:10 Introduction
- 0:40 Background
- 1:30 Study Design
- 3:05 Outcomes
- 3:25 Results
- 5:33 Discussion
- 7:57 Clinical Relevance
4:30Orforglipron: Newest Weight Loss Drug | Game Changer Or Looming Risk? | India TodayIndia TodayDetails4 key moments
According to the video, the channel presenter walks through Eli Lilly's experimental daily weight loss pill, orforglipron. The presenter says it works like other GLP-1 drugs by lowering blood sugar, slowing digestion and reducing appetite.
Everything about this video
1:54#semaglutide #tirzepatide #cagrisema #survodutide #retatrutide #oralsemaglutide #orforglipron #maridMichael Albert MD Details
In this short review, the speaker gives an overview of the new obesity drugs, starting with what is already approved and then moving through the pipeline.
Everything about this video
7:32Eli Lilly Weight Loss Pill Orforglipron- June 2023 (Health Coach Reacts)fitforfreelanceDetails4 key moments
In this video, the speaker, a health coach and founder of fit for freelance, reacts to news about Eli Lilly's oral weight loss drug orforglipron.
Everything about this videoFoundayo next steps
Foundayo prices
Experiences on other drugs
Foundayo prices move. We check daily.
Every GLP-1 program we track, ranked by what actually leaves your account.



